The Development of Drugs for Treatment of Sleeping Sickness: a Historical Review

Overview

Journal Parasit Vectors

Publisher Biomed Central

Specialties Parasitology
Tropical Medicine

Date 2010 Mar 12

PMID 20219092

Citations 82

Authors

Dietmar Steverding

Affiliations

Soon will be listed here.

Abstract

Only four drugs are available for the chemotherapy of human African trypanosomiasis or sleeping sickness; Suramin, pentamidine, melarsoprol and eflornithine. The history of the development of these drugs is well known and documented. suramin, pentamidine and melarsoprol were developed in the first half of the last century by the then recently established methods of medicinal chemistry. Eflornithine, originally developed in the 1970s as an anti-cancer drug, became a treatment of sleeping sickness largely by accident. This review summarises the developmental processes which led to these chemotherapies from the discovery of the first bioactive lead compounds to the identification of the final drugs.

Citing Articles

Combination Therapy and Phytochemical-Loaded Nanosytems for the Treatment of Neglected Tropical Diseases.

Soto-Sanchez J, Garza-Trevino G Pharmaceutics. 2024; 16(10).

PMID: 39458571 PMC: 11510106. DOI: 10.3390/pharmaceutics16101239.

Potential Trypanocidal Activity of Glycerol Analogues.

Humann R, Smith T ChemistryOpen. 2024; 13(12):e202400094.

PMID: 39263751 PMC: 11625932. DOI: 10.1002/open.202400094.

DFMO inhibition of neuroblastoma tumorigenesis.

Gandra D, Mulama D, Foureau D, McKinney K, Kim E, Smith K Cancer Med. 2024; 13(9):e7207.

PMID: 38686627 PMC: 11058673. DOI: 10.1002/cam4.7207.

Lead Optimization of the 5-Phenylpyrazolopyrimidinone NPD-2975 toward Compounds with Improved Antitrypanosomal Efficacy.

Zheng Y, van den Kerkhof M, Ibrahim M, de Esch I, Maes L, Sterk G J Med Chem. 2024; 67(4):2849-2863.

PMID: 38330051 PMC: 10895668. DOI: 10.1021/acs.jmedchem.3c01976.

Tractable Quinolone Hydrazides Exhibiting Sub-Micromolar and Broad Spectrum Antitrypanosomal Activities.

Chirwa K, Francisco K, Dube P, Park H, Legoabe L, Teixeira T ChemMedChem. 2024; 19(9):e202300667.

PMID: 38326914 PMC: 11076157. DOI: 10.1002/cmdc.202300667.

References

Meyskens Jr F, Gerner E . Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res. 1999; 5(5):945-51. View

Friedheim E . Some approaches to the development of chemotherapeutic compounds. Ann Trop Med Parasitol. 1959; 53(1):1-9. DOI: 10.1080/00034983.1959.11685892. View

Pepin J, Milord F, Meurice F, Ethier L, Loko L, Mpia B . High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg. 1992; 86(3):254-6. DOI: 10.1016/0035-9203(92)90298-q. View

Fairlamb A . Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol. 2003; 19(11):488-94. DOI: 10.1016/j.pt.2003.09.002. View

Soeiro M, de Souza E, Stephens C, Boykin D . Aromatic diamidines as antiparasitic agents. Expert Opin Investig Drugs. 2005; 14(8):957-72. DOI: 10.1517/13543784.14.8.957. View

Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, Checchi F . Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials. 2006; 1(8):e39. PMC: 1687208. DOI: 10.1371/journal.pctr.0010039. View

Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S . Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis. 2007; 45(11):1435-42. DOI: 10.1086/522982. View

Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G . Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis. 2007; 1(2):e64. PMC: 2100371. DOI: 10.1371/journal.pntd.0000064. View

FRIEDHEIM E . Melarsen oxide in the treatment of human trypanosomiasis. Ann Trop Med Parasitol. 1948; 42(3-4):357-63. DOI: 10.1080/00034983.1948.11685383. View

10.

FRIEDHEIM E . Mel B in the treatment of human trypanosomiasis. Am J Trop Med Hyg. 1949; 29(2):173-80. DOI: 10.4269/ajtmh.1949.s1-29.173. View

11.

Steverding D . The history of African trypanosomiasis. Parasit Vectors. 2008; 1(1):3. PMC: 2270819. DOI: 10.1186/1756-3305-1-3. View

12.

Bosch F, Rosich L . The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. Pharmacology. 2008; 82(3):171-9. PMC: 2790789. DOI: 10.1159/000149583. View

13.

Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U . Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009; 374(9683):56-64. DOI: 10.1016/S0140-6736(09)61117-X. View

14.

Wenzler T, Boykin D, Ismail M, Hall J, Tidwell R, Brun R . New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289. Antimicrob Agents Chemother. 2009; 53(10):4185-92. PMC: 2764217. DOI: 10.1128/AAC.00225-09. View

15.

Nightingale S . From the Food and Drug Administration. JAMA. 1991; 265(10):1229. View

16.

COLLARD P, HARGREAVES W . Neuropathy after stilbamidine; treatment of kala-azar. Lancet. 2010; 2(6480):686-8. DOI: 10.1016/s0140-6736(47)90716-2. View

17.

Pope W . SYNTHETIC THERAPEUTIC AGENTS. Br Med J. 2010; 1(3297):413-4. PMC: 2303898. DOI: 10.1136/bmj.1.3297.413. View

18.

Eozenou P, Jannin J, Ngampo S, Carme B, Tell G, Schechter P . [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo]. Med Trop (Mars). 1989; 49(2):149-54. View

19.

Pepin J, Milord F, Mpia B, Meurice F, Ethier L, Degroof D . An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg. 1989; 83(4):514-7. DOI: 10.1016/0035-9203(89)90270-8. View

20.

Pepin J, Milord F, Guern C, Schechter P . Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness. Lancet. 1987; 2(8573):1431-3. DOI: 10.1016/s0140-6736(87)91131-7. View